Novel approaches to the treatment of biliary atresia
Yang Li, Jorge A. Bezerra – 30 December 2016
The changing face of hepatic encephalopathy: A projection for the next 5 years
Debbie L. Shawcross – 30 December 2016
A framework to determine when liver transplantation is futile
Jennifer C. Lai – 30 December 2016
Managing encephalopathy in the outpatient setting
Sahaj Rathi, Radha K. Dhiman – 30 December 2016
Treatment of chronic cholestasis: What we know and what we will know?
James L. Boyer – 30 December 2016
Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and Management
- Read more about Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and Management
Dennis L. Shung, Guadalupe Garcia‐Tsao – 29 December 2016
Fecal microbiota transplantation induces hepatitis B virus e‐antigen (HBeAg) clearance in patients with positive HBeAg after long‐term antiviral therapy
Yan‐Dan Ren, Zhen‐Shi Ye, Liu‐Zhu Yang, Li‐Xin Jin, Wen‐Jun Wei, Yong‐Yue Deng, Xiao‐Xiao Chen, Chuan‐Xing Xiao, Xiao‐Fang Yu, Hong‐Zhi Xu, Li‐Zhu Xu, Yun‐Na Tang, Fei Zhou, Xue‐Lian Wang, Mei‐Ya Chen, Li‐Gang Chen, Mei‐Zhu Hong, Jian‐Lin Ren, Jin‐Shui Pan – 27 December 2016
Reply
Nicolas Goldaracena, Juan Echeverri, Markus Selzner – 27 December 2016
Decision modeling in donation after circulatory death liver transplantation
Kenneth A. McLean, Julian Camilleri‐Brennan, Stephen R. Knight, Thomas M. Drake, Riinu Ots, Catherine A. Shaw, Stephen J. Wigmore, Ewen M. Harrison – 27 December 2016 – Donation after circulatory death (DCD) liver allografts are increasingly used for transplantation. However, the posttransplantation clinical and quality of life outcomes of DCD recipients are traditionally considered to be inferior compared with donation after brain death (DBD) allograft recipients. Decision making for such marginal organs can be difficult.
Aldehyde dehydrogenase‐2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP‐activated protein kinase signaling in mice
Guojun Hou, Lei Chen, Gang Liu, Liang Li, Yuan Yang, He‐Xin Yan, Hui‐Lu Zhang, Jing Tang, Ying Cheng Yang, Ximeng Lin, Xin Chen, Gui juan Luo, Yanjing Zhu, Shanhua Tang, Jin Zhang, Hui Liu, Qingyang Gu, Ling‐Hao Zhao, Yixue Li, Lei Liu, Weiping Zhou, Hongyang Wang – 27 December 2016 – Potential biomarkers that can be used to determine prognosis and perform targeted therapies are urgently needed to treat patients with hepatocellular carcinoma (HCC).